Llobet Enrique, Tomás Juan M, Bengoechea Jose A
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Bunyola, Spain.
Program Infection and Immunity, Fundació Caubet-CIMERA Illes Balears, Bunyola, Spain.
Microbiology (Reading). 2008 Dec;154(Pt 12):3877-3886. doi: 10.1099/mic.0.2008/022301-0.
Antimicrobial peptides (APs) are important host weapons against infections. Nearly all APs are cationic and their microbicidal action is initiated through interactions with the anionic bacterial surface. It is known that pathogens have developed countermeasures to resist these agents by reducing the negative charge of membranes, by active efflux and by proteolytic degradation. Here we uncover a new strategy of resistance based on the neutralization of the bactericidal activity of APs by anionic bacterial capsule polysaccharide (CPS). Purified CPSs from Klebsiella pneumoniae K2, Streptococcus pneumoniae serotype 3 and Pseudomonas aeruginosa increased the resistance to polymyxin B of an unencapsulated K. pneumoniae mutant. Furthermore, these CPSs increased the MICs of polymyxin B and human neutrophil alpha-defensin 1 (HNP-1) for unencapsulated K. pneumoniae, Escherichia coli and P. aeruginosa PAO1. Polymyxin B or HNP-1 released CPS from capsulated K. pneumoniae, S. pneumoniae serotype 3 and P. aeruginosa overexpressing CPS. Moreover, this material also reduced the bactericidal activity of APs. We postulate that APs may trigger in vivo the release of CPS, which in turn will protect bacteria against APs. We found that anionic CPSs, but not cationic or uncharged ones, blocked the bactericidal activity of APs by binding them, thereby reducing the amount of peptides reaching the bacterial surface. Supporting this, polycations inhibited such interaction and the bactericidal activity was restored. We postulate that trapping of APs by anionic CPSs is an additional selective virulence trait of these molecules, which could be considered as bacterial decoys for APs.
抗菌肽(APs)是宿主抵抗感染的重要武器。几乎所有的抗菌肽都是阳离子性的,其杀菌作用通过与带阴离子的细菌表面相互作用而启动。已知病原体已通过降低膜的负电荷、主动外排和蛋白水解降解等方式来对抗这些抗菌剂。在此,我们发现了一种新的耐药策略,即基于阴离子细菌荚膜多糖(CPS)中和抗菌肽的杀菌活性。从肺炎克雷伯菌K2、肺炎链球菌3型和铜绿假单胞菌中纯化得到的CPS增加了无荚膜肺炎克雷伯菌突变体对多粘菌素B的耐药性。此外,这些CPS还增加了多粘菌素B和人中性粒细胞α-防御素1(HNP-1)对无荚膜肺炎克雷伯菌、大肠杆菌和铜绿假单胞菌PAO1的最低抑菌浓度(MIC)。多粘菌素B或HNP-1可从过量表达CPS的荚膜肺炎克雷伯菌、肺炎链球菌3型和铜绿假单胞菌中释放出CPS。此外,这种物质还降低了抗菌肽的杀菌活性。我们推测抗菌肽可能在体内触发CPS的释放,进而保护细菌免受抗菌肽的作用。我们发现阴离子CPS而非阳离子或不带电荷的CPS通过结合抗菌肽来阻断其杀菌活性,从而减少到达细菌表面的肽的数量。支持这一观点的是,聚阳离子抑制了这种相互作用,杀菌活性得以恢复。我们推测阴离子CPS捕获抗菌肽是这些分子的另一种选择性毒力特征,可将其视为抗菌肽的细菌诱饵。